Risk of extended viral resistance in human immunodeficiency virus-1-infected mozambican children after first-line treatment failure

Pediatric Infectious Disease Journal

Volumn 28, Issue 12, 2009, Pages

  Vaz, Paula ^a   Chaix, Marie Laure ^b,c   Jani, Ilesh ^d   MacAssa, Eugenia ^a   Bila, Dulce ^d   Vubil, Adolfo ^d   Anderson, Soren ^e   Rouzioux, Christine ^b,c   Briand, Nelly ^f,g   Blanche, Stephane ^b,c  

^a MAPUTO CENTRAL HOSPITAL   (Mozambique)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^e KAROLINSKA INSTITUTE   (Sweden)

^f INSERM   (France)

^g INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

Author keywords

HIV 1 antiretroviral resistance

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CHILD; CROSS RESISTANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MOZAMBIQUE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 74049104390     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ba6c92     Document Type: Article

References (33)

1. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300.
2. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS. 2004;18: 1905-1913.
3. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-e1140.
4. George E, Noël F, Bois G, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007;195:1411-1418.
5. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120:e856-e861.
6. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
7. Puthanakit T, Aurpibul L, Orberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956.
8. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193.
9. Kekitiinwa A, Lee KJ, Walker S, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda and the United Kingdom/Ireland. J Acquir Immune Defid Syndr. 2008;49:384-392.
10. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
11. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in ressource-limited settings: successes and challenges. AIDS. 2007;21:S5-S10.
12. Clavel F, Hance AJ. HIV drug resistance. New Engl J Med. 2004;350:1023-1035.
13. Hamers RL, Derdelinckx I, Van Vugt M, et al. The status of HIV-1 resistance ro antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008;13:625-639.
14. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-1076.
15. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41:100-107.
16. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, et al. Virologic and immu-nologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses. 2008;24:911-917.
17. Gody JC, Charpentier C, Mbitikon O, et al. High prevalence of drug resistance in HIV-1 non B sub type for African children receiving antiret-roviral regimen according WHO 2006 revised guidelines. J AIDS. 2008; 49:566-569.
18. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods. 2001;94:45-54.
19. Thompson JD, Gibson TJ, Plewniak F, et al. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876-4882.
20. Vingerhoets J, Buelens A, Letters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. XVI International HIV drug resistance workshop: basic principles and clinical implications, 12-16 June 2007, Barbados, West Indies, abstract 32. Antiviral Therapy. 2007;12:534.
21. Abreu CM, Brindeiro PA, Martins AN, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch Virol. 2008;153:2013-2017.
22. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20:F9-F13.
23. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu natal, South Africa. Clin Infect Dis. 2008;46:1589-1597.
24. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral failure: high level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first line antiret-roviral therapy. AIDS. 2009;9:1127-1134.
25. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182-4185.
26. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol. 2003;77:5685-5693.
27. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PloS Med. 2005;2:e112
28. Loemba H, Brenner B, Parniak MA, Ma'ayan S, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse tran-scriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother. 2002;46:2087-2094.
29. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5.
30. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371:1443-1451.
31. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet. 2008;371:1396-1397.
32. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44:447-452.
33. Petersen ML, Van Der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of antiretroviral therapy and regimen modification. AIDS. 2008;22:2097-2106